Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 558Leukemia 281Precursor Cell Lymphoblastic Leukemia-Lymphoma 231Lymphoma 159Myelodysplastic Syndromes 110Burkitt Lymphoma 90Congenital Abnormalities 85Lymphoma, Non-Hodgkin 84Leukemia, Monocytic, Acute 83Leukemia, Myelomonocytic, Acute 81Lymphoma, Large B-Cell, Diffuse 79Leukemia, Erythroblastic, Acute 74Leukemia, Megakaryoblastic, Acute 71Recurrence 69Lymphoma, Mantle-Cell 69Lymphoma, Follicular 48Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Hodgkin Disease 43Lymphoma, Large-Cell, Immunoblastic 36Blast Crisis 36Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 32Myeloproliferative Disorders 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell, Marginal Zone 23Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Leukemia, Basophilic, Acute 22

Interventions

Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Blood Specimen Collection 6Prednisone 5Positron Emission Tomography Computed Tomography 4Mammography 4Lenalidomide 4Colonoscopy 4pembrolizumab 3Tomography, X-Ray Computed 3Surveys and Questionnaires 3Melphalan 3Exercise 3Biopsy 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Preoperative Exercise 2Positron-Emission Tomography 2Methods 2Magnetic Resonance Imaging 2Injections 2Gemcitabine 2Educational Status 2Doxorubicin 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Disease × Cytarabine × Clear all
NCT00788892 2018-01-12

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Jazz Pharmaceuticals

Phase 2 Completed
126 enrolled 12 charts
Other hematologic neoplasm

Disease, Leukemia, Leukemia, Myeloid, Acute

NCT00143975 2010-08-12

Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

University of Ulm

Phase 2 Completed
95 enrolled
Other hematologic neoplasm

Disease, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡